Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 847409, 15 pages
http://dx.doi.org/10.1155/2011/847409
Research Article

Potential for Modulation of the Fas Apoptotic Pathway by Epidermal Growth Factor in Sarcomas

1Department of Orthopaedics, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT 84112, USA
2Sarcoma Services, Center for Children, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT 84112, USA
3Divison of Pediatric Oncology, The University of Utah, Salt Lake City, UT 84112, USA

Received 24 June 2011; Revised 22 August 2011; Accepted 23 August 2011

Academic Editor: Luca Sangiorgi

Copyright © 2011 David E. Joyner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. L. Staals, P. Bacchini, and F. Bertoni, “Dedifferentiated central chondrosarcoma,” Cancer, vol. 106, no. 12, pp. 2682–2691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. Randall and B. H. Hoang, “Musculoskeletal oncology,” in Orthopedics. Current Diagnosis and Treatment, H. B. Skinner, Ed., p. 298, McGraw–Hill, New York, NY, USA, 2006. View at Google Scholar
  3. V. Subbiah, P. Anderson, A. J. Lazar, E. Burdett, K. Raymond, and J. A. Ludwig, “Ewing's sarcoma: standard and experimental treatment options,” Current Treatment Options in Oncology, vol. 10, no. 1-2, pp. 126–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. E. Joyner, K. H. Albritton, J. D. Bastar, and R. L. Randall, “G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line,” Journal of Orthopaedic Research, vol. 24, no. 3, pp. 474–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Siegmund, D. Mauri, N. Peters et al., “Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway,” Journal of Biological Chemistry, vol. 276, no. 35, pp. 32585–32590, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Peter, R. C. Budd, J. Desbarats et al., “The CD95 receptor: apoptosis revisited,” Cell, vol. 129, no. 3, pp. 447–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Non-apoptotic Fas signaling,” Cytokine and Growth Factor Reviews, vol. 14, no. 1, pp. 53–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Hao, B. Hampel, H. Yagita, and K. Rajewsky, “T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis,” Journal of Experimental Medicine, vol. 199, no. 10, pp. 1355–1365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Zhang, Q. Liu, M. Zhang, Y. Yu, X. Liu, and X. Cao, “Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE,” Journal of Immunology, vol. 182, no. 6, pp. 3801–3808, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Almendro, E. Ametller, S. García-Recio et al., “The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin,” PLoS ONE, vol. 4, no. 3, Article ID e4728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Sjöström, C. Blomqvist, K. Von Boguslawski et al., “The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer,” Clinical Cancer Research, vol. 8, no. 3, pp. 811–816, 2002. View at Google Scholar
  12. N. V. Koshkina, E. S. Kleinerman, G. Li, C. C. Zhao, Q. Wei, and E. M. Sturgis, “Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 12, pp. 815–821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Zhou, E. A. Lafleur, N. V. Koshkina, L. L. Worth, M. S. Lester, and E. S. Kleinerman, “Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity,” Molecular Cancer Research, vol. 3, no. 12, pp. 685–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Wajant, “The Fas signaling pathway: more than a paradigm,” Science, vol. 296, no. 5573, pp. 1635–1636, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Y. Mo and W. T. Beck, “DNA damage signals induction of Fas ligand in tumor cells,” Molecular Pharmacology, vol. 55, no. 2, pp. 216–222, 1999. View at Google Scholar · View at Scopus
  16. G. Brumatti, M. Yon, F. A. Castro et al., “Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide,” Experimental Cell Research, vol. 314, no. 3, pp. 554–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Song and Y. J. Lee, “Daxx deletion mutant (amino acids 501-625)-induced apoptosis occurs through the JNK/p38-Bax-dependent mitochondrial pathway,” Journal of Cellular Biochemistry, vol. 92, no. 6, pp. 1257–1270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Perlman, W. P. Schiemann, M. W. Brooks, H. F. Lodish, and R. A. Weinberg, “TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation,” Nature Cell Biology, vol. 3, no. 8, pp. 708–714, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Linkermann, J. Qian, M. Lettau, D. Kabelitz, and O. Janssen, “Considering Fas ligand as a target for therapy,” Expert Opinion on Therapeutic Targets, vol. 9, no. 1, pp. 119–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Bremer, M. de Bruyn, H. Wajant, and W. Helfrich, “Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family,” Current Drug Targets, vol. 10, no. 2, pp. 94–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Watermann, J. Gerspach, M. Lehne et al., “Activation of CD95L fusion protein prodrugs by tumor-associated proteases,” Cell Death and Differentiation, vol. 14, no. 4, pp. 765–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. ElOjeimy, J. C. McKillop, A. M. El-Zawahry et al., “FasL gene therapy: a new therapeutic modality for head and neck cancer,” Cancer Gene Therapy, vol. 13, no. 8, pp. 739–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Fotin-Mleczek, F. Henkler, D. Samel et al., “Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8,” Journal of Cell Science, vol. 115, no. 13, pp. 2757–2770, 2002. View at Google Scholar · View at Scopus
  24. D. Siegmund, A. Wicovsky, I. Schmitz et al., “Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing,” Molecular and Cellular Biology, vol. 25, no. 15, pp. 6363–6379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Gibson, S. Tu, R. Oyer, S. M. Anderson, and G. L. Johnson, “Epidermal growth factor protects epithelial cells against Fas-induced apoptosis: requirement for Akt activation,” Journal of Biological Chemistry, vol. 274, no. 25, pp. 17612–17618, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. H. J. Zhu, J. Iaria, S. Orchard, F. Walker, and A. W. Burgess, “Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand,” Growth Factors, vol. 21, no. 1, pp. 15–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. P. Tétreault, P. Chailler, J. F. Beaulieu, N. Rivard, and D. Ménard, “Specific signaling cascades involved in cell spreading during healing of micro-wounded gastric epithelial monolayers,” Journal of Cellular Biochemistry, vol. 105, no. 5, pp. 1240–1249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Fernandes, S. Cohen, and S. Bishayee, “Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/ΔEGFR) expressed in cancer cells,” Journal of Biological Chemistry, vol. 276, no. 7, pp. 5375–5383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Zhou, L. Qiu, Y. Sun et al., “Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells,” International Journal of Oncology, vol. 29, no. 1, pp. 269–278, 2006. View at Google Scholar · View at Scopus
  30. G. Sheng, J. Guo, and B. W. Warner, “Epidermal growth factor receptor signaling modulates apoptosis via p38α MAPK-dependent activation of Bax in intestinal epithelial cells,” American Journal of Physiology, vol. 293, no. 3, pp. G599–G606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. X. Liu, B. S. Henson, Y. Zhou, N. J. D'Silva, and C. M. Mistretta, “Fungiform papilla pattern: EGF regulates inter-papilla lingual epithelium and decreases papilla number by means of PI3K/Akt, MEK/ERK, and p38 MAPK signaling,” Developmental Dynamics, vol. 237, no. 9, pp. 2378–2393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Wang, H. D. Edington, D. M. Jukic, U. N. M. Rao, S. R. Land, and J. M. Kirkwood, “Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma,” Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1315–1321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Herbst, “Review of epidermal growth factor receptor biology,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 2, supplement, pp. 21–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Y. Ilio, J. A. Sensibar, and C. Lee, “Effect of TGF-β1, TGF-α, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture,” Journal of Andrology, vol. 16, no. 6, pp. 482–490, 1995. View at Google Scholar · View at Scopus
  35. O. Lanvin, P. Guglielmi, V. Fuentes et al., “TGF-β1 modulates fas (APO-1/CD95)-mediated apoptosis of human pre-B cell lines,” European Journal of Immunology, vol. 33, no. 5, pp. 1372–1381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. G. Kim, H. S. Jong, T. Y. Kim et al., “Transforming growth factor-β1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells,” Molecular Biology of the Cell, vol. 15, no. 2, pp. 420–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. D. E. Joyner, T. A. Damron, A. J. Aboulafia, and R. L. Randall, “Oncogene coexpression in mesenchymal neoplasia correlates with EGF transcription,” Clinical Orthopaedics and Related Research, no. 459, pp. 14–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. D. E. Joyner, A. J. Aboulafia, T. A. Damron, and R. L. Randall, “Fas death pathway in sarcomas correlates with epidermal growth factor transcription,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2092–2098, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Obayashi and K. Kinoshita, “Rank of correlation coefficient as a comparable measure for biological significance of gene coexpression,” DNA Research, vol. 16, no. 5, pp. 249–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. V. F. Bernardes, F. O. Gleber-Netto, S. F. Sousa, T. A. Silva, M. H. Abreu, and M. C. Aguiar, “EGF in saliva and tumor samples of oral squamous cell carcinoma,” Applied Immunohistochemistry & Molecular Morphology. In press.
  41. C. D. Gerharz, U. Ramp, P. Reinecke et al., “Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell linesclues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma,” European Journal of Cancer, vol. 36, no. 9, pp. 1171–1179, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Shimizu, T. Yoshimoto, M. Sato, J. Morimoto, A. Matsuzawa, and Y. Takeda, “Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor,” International Journal of Cancer, vol. 114, no. 6, pp. 926–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. H. U. Kontny, T. M. Lehrnbecher, S. J. Chanock, and C. L. Mackall, “Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma,” Cancer Research, vol. 58, no. 24, pp. 5842–5849, 1998. View at Google Scholar · View at Scopus
  44. J. Allison, H. M. Georgiou, A. Strasser, and D. L. Vaux, “Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 3943–3947, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. A. E. Ryan, S. Lane, F. Shanahan, J. O'Connell, and A. M. Houston, “Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data,” Journal of Carcinogenesis, vol. 5, p. 5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Shakunaga, T. Ozaki, N. Ohara et al., “Expression of connective tissue growth factor in cartilaginous tumors,” Cancer, vol. 89, no. 7, pp. 1466–1473, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Obayashi and K. Kinoshita, “Coexpression landscape in ATTED-II: usage of gene list and gene network for various types of pathways,” Journal of Plant Research, vol. 123, no. 3, pp. 311–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Prifti, J. D. Zucker, K. Clement, and C. Henegar, “FunNet: an integrative tool for exploring transcriptional interactions,” Bioinformatics, vol. 24, no. 22, pp. 2636–2638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. P. Ficklin, F. Luo, and F. A. Feltus, “The association of multiple interacting genes with specific phenotypes in rice using gene coexpression networks,” Plant Physiology, vol. 154, no. 1, pp. 13–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Schneckener, L. Görlitz, H. Ellinger-Ziegelbauer, H. J. Ahr, and A. Schuppert, “An elastic network model to identify characteristic stress response genes,” Computational Biology and Chemistry, vol. 34, no. 3, pp. 193–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Wu, X. Feng, and L. Stein, “A human functional protein interaction network and its application to cancer data analysis,” Genome Biology, vol. 11, no. 5, p. R53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Towfic, S. VanderPIas, C. A. OIiver et al., “Detection of gene orthology from gene co-expression and protein interaction networks,” BMC Bioinformatics, vol. 11, supplement 3, article S7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. B. C. Barnhart, E. C. Alappat, and M. E. Peter, “The CD95 Type I/Type II model,” Seminars in Immunology, vol. 15, no. 3, pp. 185–193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. E. Peter, P. Legembre, and B. C. Barnhart, “Does CD95 have tumor promoting activities?” Biochimica et Biophysica Acta, vol. 1755, no. 1, pp. 25–36, 2005. View at Publisher · View at Google Scholar
  55. M. H. Werner, C. Wu, and C. M. Walsh, “Emerging roles for the death adaptor FADD in death receptor avidity and cell cycle regulation,” Cell Cycle, vol. 5, no. 20, pp. 2332–2338, 2006. View at Google Scholar · View at Scopus
  56. P. Salomoni and A. F. Khelifi, “Daxx: death or survival protein?” Trends in Cell Biology, vol. 16, no. 2, pp. 97–104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. C. R. Lindsay, S. Giovinazzi, and A. M. Ishov, “Daxx is a predominately nuclear protein that does not translocate to the cytoplasm in response to cell stress,” Cell Cycle, vol. 8, no. 10, pp. 1544–1551, 2009. View at Google Scholar · View at Scopus
  58. A. B. Pardee, “A restriction point for control of normal animal cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 4, pp. 1286–1290, 1974. View at Google Scholar · View at Scopus
  59. X. Cui, H. J. Kim, I. Kuiatse, H. Kim, P. H. Brown, and A. V. Lee, “Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell migration,” Cancer Research, vol. 66, no. 10, pp. 5304–5313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. H. Trang, D. E. Joyner, T. A. Damron, A. J. Aboulafia, and R. Lor Randall, “Potential for functional redundancy in EGF and TGFα signaling in desmoid cells: a cDNA microarray analysis,” Growth Factors, vol. 28, no. 1, pp. 10–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Mori, M. Hinchcliff, M. Wu, M. Warner-Blankenship, K. M. Lyons, and J. Varga, “Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-β responsiveness,” Experimental Cell Research, vol. 314, no. 5, pp. 1094–1104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Funaba, T. Ikeda, M. Murakami et al., “Involvement of p38 MAP kinase and Smad3 in TGF-β-mediated mast cell functions,” Cellular Signalling, vol. 18, no. 12, pp. 2154–2161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Samarakoon, C. E. Higgins, S. P. Higgins, and P. J. Higgins, “Differential requirement for MEK/ERK and SMAD signaling in PAI-1 and CTGF expression in response to microtubule disruption,” Cellular Signalling, vol. 21, no. 6, pp. 986–995, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. N. A. Wahab, B. S. Weston, and R. M. Mason, “Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 340–351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. D. E. Joyner, S. H. Trang, T. A. Damron, A. J. Aboulafia, J. E. Cummings, and R. L. Randall, “Desmoid cell motility is induced in vitro by rhEGF,” Journal of Orthopaedic Research, vol. 27, no. 9, pp. 1258–1262, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Lund-Johansen, R. Bjerkvig, P. A. Humphrey, S. H. Bigner, D. D. Bigner, and O. D. Laerum, “Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro,” Cancer Research, vol. 50, no. 18, pp. 6039–6044, 1990. View at Google Scholar · View at Scopus
  67. H. Nakamura, A. Kawakami, H. Ida, T. Koji, and K. Eguchi, “Epidermal growth factor inhibits Fas-mediated apoptosis in salivary epithelial cells of patients with primary Sjögren's syndrome,” Clinical and Experimental Rheumatology, vol. 25, no. 6, pp. 831–837, 2007. View at Google Scholar · View at Scopus
  68. V. H. Fan, K. Tamama, A. Au et al., “Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells,” Stem Cells, vol. 25, no. 5, pp. 1241–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Omoteyama and S. Inoue, “The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors,” Biochemical and Biophysical Research Communications, vol. 353, no. 1, pp. 159–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. J. A. Handler, R. M. Danilowicz, and T. E. Eling, “Mitogenic signaling by epidermal growth factor (EGF), but not platelet-derived growth factor, requires arachidonic acid metabolism in BALB/c 3T3 cells. Modulation of EGF-dependent c-myc expression by prostaglandins,” Journal of Biological Chemistry, vol. 265, no. 7, pp. 3669–3673, 1990. View at Google Scholar · View at Scopus
  71. H. A. David and M. P. Rogers, “Order statistics in overlapping samples, moving order statistics and u-statistics,” Biometrika, vol. 70, no. 1, pp. 245–249, 1983. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Reinehr, A. Sommerfeld, and D. Häussinger, “CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells,” Gastroenterology, vol. 134, no. 5, pp. 1494–1506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Goillot, J. Raingeaud, A. Ranger et al., “Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3302–3307, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. S. M. Farley, D. E. Purdy, O. P. Ryabinina, P. Schneider, B. E. Magun, and M. S. Iordanov, “Fas ligand-induced proinflammatory transcriptional responses in reconstructed human epidermis: recruitment of the epidermal growth factor receptor and activation of MAP kinases,” Journal of Biological Chemistry, vol. 283, no. 2, pp. 919–928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Yoshimoto and M. Imoto, “Induction of EGF-dependent apoptosis by vacuolar-type H+-ATPase inhibitors in A431 cells overexpressing the EGF receptor,” Experimental Cell Research, vol. 279, no. 1, pp. 118–127, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. G. R. Grotendorst and M. R. Duncan, “Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation,” FASEB Journal, vol. 19, no. 7, pp. 729–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Inoki, T. Shiomi, G. Hashimoto et al., “Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis,” FASEB Journal, vol. 16, no. 2, pp. 219–221, 2002. View at Google Scholar · View at Scopus
  78. S. Mercurio, B. Latinkic, N. Itasaki, R. Krumlauf, and J. C. Smith, “Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex,” Development, vol. 131, no. 9, pp. 2137–2147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Chen, S. M. Park, A. V. Tumanov et al., “CD95 promotes tumour growth,” Nature, vol. 465, no. 7297, pp. 492–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. C. C. Yu, M. J. Hsu, M. L. Kuo et al., “Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway,” Journal of Immunology, vol. 182, no. 12, pp. 7916–7927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Chang and X. Y. Wu, “JNK1/2 siRNA inhibits transforming-growth factor-β1-induced connective tissue growth factor expression and fibrotic function in THSFs,” Molecular and Cellular Biochemistry, vol. 335, no. 1-2, pp. 83–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Y. Wang, P. S. Chen, E. Prakash et al., “Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and clap1,” Cancer Research, vol. 69, no. 8, pp. 3482–3491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Wahab, D. Cox, A. Witherden, and R. M. Mason, “Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1),” Biochemical Journal, vol. 406, no. 1, pp. 131–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Hayata, Y. Fujio, Y. Yamamoto et al., “Connective tissue growth factor induces cardiac hypertrophy through Akt signaling,” Biochemical and Biophysical Research Communications, vol. 370, no. 2, pp. 274–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. T. H. Holmström, S. C. Chow, I. Elo et al., “Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling,” Journal of Immunology, vol. 160, no. 6, pp. 2626–2636, 1998. View at Google Scholar · View at Scopus
  86. S. E. F. Tran, T. H. Holmström, M. Ahonen, V. M. Kähäri, and J. E. Eriksson, “MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16484–16490, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. B. P. Eliceiri, R. Klemke, S. Strömblad, and D. A. Cheresh, “Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis,” Journal of Cell Biology, vol. 140, no. 5, pp. 1255–1263, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Gao and D. R. Brigstock, “Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of Its C-terminal domain to integrin αvβ3 and heparan sulfate proteoglycan,” Journal of Biological Chemistry, vol. 279, no. 10, pp. 8848–8855, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. J. D. Hood, R. Frausto, W. B. Kiosses, M. A. Schwartz, and D. A. Cheresh, “Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis,” Journal of Cell Biology, vol. 162, no. 5, pp. 933–943, 2003. View at Publisher · View at Google Scholar · View at Scopus